Supervisor Database Search
Guidance for ICAT Supervisors
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.
You can read about the ICAT supervisor selection process and eligibility criteria below:
Terms of reference/guide to supervising ICAT Fellows.
You can read the terms of reference for supervisors actively supervising ICAT Fellows below:
Supervisor Database
Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameProfessor Noel G McElvaney
- genetics, genomics and molecular biology
- infectious disease and the immune system
- Medicine
- Respiratory Medicine
I have a strong track record in translational research and have published widely in the areas of cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AATD), emphysema and lung inflammation. My laboratory is now recognized as one of the major units investigating the protease-anti protease balance in lung disease. The unit also has an international reputation in the areas of neutrophil activation, ER stress, airway signal transduction and more recently post translational modification of defense proteins in lung disease.
I have placed strong emphasis on the translation of my research findings to patient care and a substantial volume of my work has led to significant interactions with pharmaceutical companies worldwide. Recent examples of my research include the publication of a novel biomarker for identification of fungal-sensitization in patients with CF (J Allergy Clin Immunol, 2016), and how treatment with the ion channel potentiator ivacaftor normalized CF neutrophil ion levels and bacterial killing (Blood, 2014).
In 2015, I was principal investigator of a study investigating the efficacy of alpha-1 proteinase inhibitor augmentation treatment for AATD (Lancet) and have intensely published on the ability of this treatment to correct neutrophil function (J Clin Invest, 2010; Sci Transl Med, 2014). In addition, my laboratory was the first to definitively show increased risk of COPD in people heterozygous for AATD who smoke (Am J Respir Crit Care Med. 2014).